Nanotechnology platforms for antigen and immunostimulant delivery in vaccine formulations

Autores
Márquez, Patricio Guillermo; Wolman, Federico Javier; Glisoni, Romina Julieta
Año de publicación
2024
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
Vaccines represent a cornerstone in global health history, marking one of the most significant scientific achievements. Initially consisting of live or attenuated microorganisms, vaccines have evolved to include subunit vaccines, which offer greater specificity, safety, and production advantages. However, subunit vaccines require adjuvants due to the low immunogenicity of their antigens. These adjuvants include immunostimulatory molecules and particulate systems, which serve as carriers for both antigens and immunostimulants. The nanoscale dimensions of these particulate systems confer distinct advantages. This review comprehensively discusses FDA andEMA-approved vaccines that incorporate adjuvants, emphasizing the growing use of nanoparticulate adjuvants in enhancing vaccine efficacy and safety. The unique physicochemical properties of nanoscopic systems, such as hydrodynamic size, shape, surface charge, hydrophobicity and degradation profiles are explored, that determine their effectiveness in vaccine formulations.Furthermore, innovations in production scalability and alternative delivery routes, such as oral or transdermalvaccines, offer promising solutions to global vaccine accessibility challenges, particularly in resource-limitedsettings. The ongoing integration of nanotechnology platforms thus continues to expand the potential of vaccines,ensuring safer, more effective, and more accessible solutions for global immunization efforts.
Fil: Márquez, Patricio Guillermo. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Nanobiotecnología. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Instituto de Nanobiotecnología; Argentina
Fil: Wolman, Federico Javier. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Nanobiotecnología. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Instituto de Nanobiotecnología; Argentina
Fil: Glisoni, Romina Julieta. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Nanobiotecnología. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Instituto de Nanobiotecnología; Argentina
Materia
Nanotechnology platforms
Vaccines
Antigens
Adjuvants
Nivel de accesibilidad
acceso abierto
Condiciones de uso
https://creativecommons.org/licenses/by-nc-nd/2.5/ar/
Repositorio
CONICET Digital (CONICET)
Institución
Consejo Nacional de Investigaciones Científicas y Técnicas
OAI Identificador
oai:ri.conicet.gov.ar:11336/256787
Acceder
id CONICETDig_f985694613a85ae55cc96b0d2b04ffd9
oai_identifier_str oai:ri.conicet.gov.ar:11336/256787
network_acronym_str CONICETDig
repository_id_str 3498
network_name_str CONICET Digital (CONICET)
spelling Nanotechnology platforms for antigen and immunostimulant delivery in vaccine formulationsMárquez, Patricio GuillermoWolman, Federico JavierGlisoni, Romina JulietaNanotechnology platformsVaccinesAntigensAdjuvantshttps://purl.org/becyt/ford/2.10https://purl.org/becyt/ford/2Vaccines represent a cornerstone in global health history, marking one of the most significant scientific achievements. Initially consisting of live or attenuated microorganisms, vaccines have evolved to include subunit vaccines, which offer greater specificity, safety, and production advantages. However, subunit vaccines require adjuvants due to the low immunogenicity of their antigens. These adjuvants include immunostimulatory molecules and particulate systems, which serve as carriers for both antigens and immunostimulants. The nanoscale dimensions of these particulate systems confer distinct advantages. This review comprehensively discusses FDA andEMA-approved vaccines that incorporate adjuvants, emphasizing the growing use of nanoparticulate adjuvants in enhancing vaccine efficacy and safety. The unique physicochemical properties of nanoscopic systems, such as hydrodynamic size, shape, surface charge, hydrophobicity and degradation profiles are explored, that determine their effectiveness in vaccine formulations.Furthermore, innovations in production scalability and alternative delivery routes, such as oral or transdermalvaccines, offer promising solutions to global vaccine accessibility challenges, particularly in resource-limitedsettings. The ongoing integration of nanotechnology platforms thus continues to expand the potential of vaccines,ensuring safer, more effective, and more accessible solutions for global immunization efforts.Fil: Márquez, Patricio Guillermo. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Nanobiotecnología. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Instituto de Nanobiotecnología; ArgentinaFil: Wolman, Federico Javier. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Nanobiotecnología. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Instituto de Nanobiotecnología; ArgentinaFil: Glisoni, Romina Julieta. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Nanobiotecnología. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Instituto de Nanobiotecnología; ArgentinaElsevier2024-12info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfapplication/pdfapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/256787Márquez, Patricio Guillermo; Wolman, Federico Javier; Glisoni, Romina Julieta; Nanotechnology platforms for antigen and immunostimulant delivery in vaccine formulations; Elsevier; Nano Trends; 8; 12-2024; 1-202666-9781CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/url/https://linkinghub.elsevier.com/retrieve/pii/S266697812400028Xinfo:eu-repo/semantics/altIdentifier/doi/10.1016/j.nwnano.2024.100058info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-nd/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-09-03T09:56:27Zoai:ri.conicet.gov.ar:11336/256787instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-09-03 09:56:28.264CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse
dc.title.none.fl_str_mv Nanotechnology platforms for antigen and immunostimulant delivery in vaccine formulations
title Nanotechnology platforms for antigen and immunostimulant delivery in vaccine formulations
spellingShingle Nanotechnology platforms for antigen and immunostimulant delivery in vaccine formulations
Márquez, Patricio Guillermo
Nanotechnology platforms
Vaccines
Antigens
Adjuvants
title_short Nanotechnology platforms for antigen and immunostimulant delivery in vaccine formulations
title_full Nanotechnology platforms for antigen and immunostimulant delivery in vaccine formulations
title_fullStr Nanotechnology platforms for antigen and immunostimulant delivery in vaccine formulations
title_full_unstemmed Nanotechnology platforms for antigen and immunostimulant delivery in vaccine formulations
title_sort Nanotechnology platforms for antigen and immunostimulant delivery in vaccine formulations
dc.creator.none.fl_str_mv Márquez, Patricio Guillermo
Wolman, Federico Javier
Glisoni, Romina Julieta
author Márquez, Patricio Guillermo
author_facet Márquez, Patricio Guillermo
Wolman, Federico Javier
Glisoni, Romina Julieta
author_role author
author2 Wolman, Federico Javier
Glisoni, Romina Julieta
author2_role author
author
dc.subject.none.fl_str_mv Nanotechnology platforms
Vaccines
Antigens
Adjuvants
topic Nanotechnology platforms
Vaccines
Antigens
Adjuvants
purl_subject.fl_str_mv https://purl.org/becyt/ford/2.10
https://purl.org/becyt/ford/2
dc.description.none.fl_txt_mv Vaccines represent a cornerstone in global health history, marking one of the most significant scientific achievements. Initially consisting of live or attenuated microorganisms, vaccines have evolved to include subunit vaccines, which offer greater specificity, safety, and production advantages. However, subunit vaccines require adjuvants due to the low immunogenicity of their antigens. These adjuvants include immunostimulatory molecules and particulate systems, which serve as carriers for both antigens and immunostimulants. The nanoscale dimensions of these particulate systems confer distinct advantages. This review comprehensively discusses FDA andEMA-approved vaccines that incorporate adjuvants, emphasizing the growing use of nanoparticulate adjuvants in enhancing vaccine efficacy and safety. The unique physicochemical properties of nanoscopic systems, such as hydrodynamic size, shape, surface charge, hydrophobicity and degradation profiles are explored, that determine their effectiveness in vaccine formulations.Furthermore, innovations in production scalability and alternative delivery routes, such as oral or transdermalvaccines, offer promising solutions to global vaccine accessibility challenges, particularly in resource-limitedsettings. The ongoing integration of nanotechnology platforms thus continues to expand the potential of vaccines,ensuring safer, more effective, and more accessible solutions for global immunization efforts.
Fil: Márquez, Patricio Guillermo. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Nanobiotecnología. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Instituto de Nanobiotecnología; Argentina
Fil: Wolman, Federico Javier. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Nanobiotecnología. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Instituto de Nanobiotecnología; Argentina
Fil: Glisoni, Romina Julieta. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Nanobiotecnología. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Instituto de Nanobiotecnología; Argentina
description Vaccines represent a cornerstone in global health history, marking one of the most significant scientific achievements. Initially consisting of live or attenuated microorganisms, vaccines have evolved to include subunit vaccines, which offer greater specificity, safety, and production advantages. However, subunit vaccines require adjuvants due to the low immunogenicity of their antigens. These adjuvants include immunostimulatory molecules and particulate systems, which serve as carriers for both antigens and immunostimulants. The nanoscale dimensions of these particulate systems confer distinct advantages. This review comprehensively discusses FDA andEMA-approved vaccines that incorporate adjuvants, emphasizing the growing use of nanoparticulate adjuvants in enhancing vaccine efficacy and safety. The unique physicochemical properties of nanoscopic systems, such as hydrodynamic size, shape, surface charge, hydrophobicity and degradation profiles are explored, that determine their effectiveness in vaccine formulations.Furthermore, innovations in production scalability and alternative delivery routes, such as oral or transdermalvaccines, offer promising solutions to global vaccine accessibility challenges, particularly in resource-limitedsettings. The ongoing integration of nanotechnology platforms thus continues to expand the potential of vaccines,ensuring safer, more effective, and more accessible solutions for global immunization efforts.
publishDate 2024
dc.date.none.fl_str_mv 2024-12
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/11336/256787
Márquez, Patricio Guillermo; Wolman, Federico Javier; Glisoni, Romina Julieta; Nanotechnology platforms for antigen and immunostimulant delivery in vaccine formulations; Elsevier; Nano Trends; 8; 12-2024; 1-20
2666-9781
CONICET Digital
CONICET
url http://hdl.handle.net/11336/256787
identifier_str_mv Márquez, Patricio Guillermo; Wolman, Federico Javier; Glisoni, Romina Julieta; Nanotechnology platforms for antigen and immunostimulant delivery in vaccine formulations; Elsevier; Nano Trends; 8; 12-2024; 1-20
2666-9781
CONICET Digital
CONICET
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv info:eu-repo/semantics/altIdentifier/url/https://linkinghub.elsevier.com/retrieve/pii/S266697812400028X
info:eu-repo/semantics/altIdentifier/doi/10.1016/j.nwnano.2024.100058
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
https://creativecommons.org/licenses/by-nc-nd/2.5/ar/
eu_rights_str_mv openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by-nc-nd/2.5/ar/
dc.format.none.fl_str_mv application/pdf
application/pdf
application/pdf
application/pdf
application/pdf
dc.publisher.none.fl_str_mv Elsevier
publisher.none.fl_str_mv Elsevier
dc.source.none.fl_str_mv reponame:CONICET Digital (CONICET)
instname:Consejo Nacional de Investigaciones Científicas y Técnicas
reponame_str CONICET Digital (CONICET)
collection CONICET Digital (CONICET)
instname_str Consejo Nacional de Investigaciones Científicas y Técnicas
repository.name.fl_str_mv CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas
repository.mail.fl_str_mv dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar
_version_ 1842269404023226368
score 13.13397

Publicaciones similares